PMID: 7546837Jan 1, 1995Paper

High-dose therapy with autologous bone marrow stem cell support in primary and metastatic human breast cancer. A review

Acta Oncologica
J Bergh

Abstract

A dose-response relationship has been demonstrated for metastatic human breast cancer. This increased response using moderately increased doses is generally not translated into an improved survival. The use of high-dose therapy to selected patients with metastases/recurrence responding to conventional doses of polychemotherapy may lead to an improved survival tail. Conventional doses of polychemotherapy in the adjuvant setting will reduce the relative mortality by around 25% 10 years after primary diagnosis. The use of high-dose therapy supported by autologous bone marrow stem cells may be markedly more effective in the adjuvant setting, especially to high-risk patients, compared with standard polychemotherapy. Several randomized studies are being planned or have already started in order to answer different aspects of this issue.

References

May 1, 1977·Cancer·R M O'BryanB Hoogstraten
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M Eddy
Nov 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S F WilliamsJ D Bitran
Jul 1, 1992·Current Problems in Cancer·G D Demetri
Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K AntmanL E Schnipper
Oct 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J CoteM P Osborne
Nov 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R WallersteinM Ewer
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P EderE Frei
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F R DunphyR O Wallerstein
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F TannockH Sutherland
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P PetersJ O Moore
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I C HendersonR Gelman
Apr 1, 1988·Annals of Internal Medicine·K Antman, R P Gale
Oct 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J AisnerJ F Holland
Mar 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G N HortobagyiV Rodriguez
Nov 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Hryniuk, H Bush
Jun 1, 1982·American Journal of Clinical Oncology·A A ForastiereR E Wittes
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L J AyashR Gonin
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J CrownC Hudis
May 5, 1994·The New England Journal of Medicine·W C WoodC R Ferree
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C FocanF Ries
May 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H M Pinedo
Jan 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K H Antman, R L Souhami
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·N H MulderE G de Vries
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P PetersE Shpall
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S ColdC Rose
Sep 1, 1995·Blood Reviews·L Vahdat, K Antman

❮ Previous
Next ❯

Citations

Dec 9, 2003·The Breast : Official Journal of the European Society of Mastology·Jonas Bergh
Dec 28, 1999·Acta Oncologica·J Bergh
Jul 10, 2001·Acta Oncologica·J BerghUNKNOWN SBU-group. Swedish Council of Technology Assessment in Health Care

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.